Organon & Co. (OGN) To Go Ex-Dividend on November 12th

Organon & Co. (NYSE:OGN) announced a quarterly dividend on Thursday, October 31st, Zacks reports. Shareholders of record on Tuesday, November 12th will be given a dividend of 0.28 per share on Thursday, December 12th. This represents a $1.12 annualized dividend and a yield of 6.19%. The ex-dividend date is Tuesday, November 12th.

Organon & Co. has a dividend payout ratio of 24.8% meaning its dividend is sufficiently covered by earnings. Research analysts expect Organon & Co. to earn $4.18 per share next year, which means the company should continue to be able to cover its $1.12 annual dividend with an expected future payout ratio of 26.8%.

Organon & Co. Stock Down 3.7 %

Shares of OGN opened at $18.08 on Friday. The company has a market capitalization of $4.66 billion, a price-to-earnings ratio of 4.65, a PEG ratio of 0.81 and a beta of 0.84. Organon & Co. has a 52 week low of $10.84 and a 52 week high of $23.10. The stock’s 50-day moving average price is $19.38 and its 200-day moving average price is $20.10. The company has a quick ratio of 1.17, a current ratio of 1.64 and a debt-to-equity ratio of 60.05.

Organon & Co. (NYSE:OGN) last posted its earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.04. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. The firm had revenue of $1.61 billion during the quarter, compared to analyst estimates of $1.61 billion. During the same period in the previous year, the firm earned $1.31 EPS. The business’s quarterly revenue was down .1% on a year-over-year basis. On average, sell-side analysts predict that Organon & Co. will post 4.04 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on OGN shares. Evercore ISI raised shares of Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. cut Organon & Co. from a “neutral” rating to an “underweight” rating and boosted their price objective for the company from $18.00 to $20.00 in a research report on Friday, September 6th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.